PDF《长春达兴药业股份有限公司》

C

1 C * For identification purposes only The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

长春达兴药业股份有限公司CHANGCHUN DA XING PHARMACEUTICAL COMPANY LIMITED* (a joint stock limited company incorporated in the People's Republic of China) (Stock Code: 8067) RESIGNATION OF QUALIFIED ACCOUNTANT, COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE The Company announces that Mr Yau Wing Yiu has tendered his resignation as qualified accountant, company secretary and authorized representative of the Company with effect from

21 October 2005. Mr Zhang Dong Hai, an executive director of the Company, has been appointed as an authorized representative of the Company with effect from

21 October 2005. Trading in the shares of the Company on the Stock Exchange was suspended from

28 July

2005 and will remain suspended until further notice. Changchun Da Xing Pharmaceutical Company Limited (the "Company") announces that Mr Yau Wing Yiu has tendered his resignation as qualified accountant, company secretary and authorized representative of the Company with effect from

21 October

2005 for his personal business pursuit. The Company also announces that Mr Zhang Dong Hai, an executive director of the Company, has been appointed as an authorized representative of the Company with effect from

21 October 2005. As at the date of this announcement, the Company has not yet identified suitable candidate for qualified accountant and company secretary. As such, the Company failed to comply with Rule 5.15 of the Rules Governing the Listing of Securities on the Growth Enterprise Market ("GEM Listing Rules") which requires the Company, at all time, to employ a qualified accountant at full time basis. The Company is identifying suitable candidates for the captioned positions and will make further announcement upon the appointment of the captioned positions. The Stock Exchange reserves the right to take appropriate action for the breach of GEM Listing Rules. C

2 C Trading in the shares of the Company on the Stock Exchange was suspended from

28 July

2005 and will remain suspended until further notice. By order of the Board Changchun Da Xing Pharmaceutical Company Limited Qu Lian Qin Chairman Changchun, the PRC,

20 October

2005 As at the date of this announcement the Board comprises five executive directors, being Qu Lian Qin, Yu Cheng Kun, Lu De Yi, Guo Bin and Zhang Dong Hai;

a non-executive director, Dong Guo Zhi;

and three independent non-executive directors, being Yang Shi Jie, Sun Xiao Bo and Zhang Zhong Sheng. At the time of issuance of this announcement, the Company is unable to contact Mr Sun Xiao Bo. This announcement, for which the directors of Changchun Da Xing Pharmaceutical Company Limited (the "Directors") collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to Changchun Da Xing Pharmaceutical Company Limited. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading;